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A balanced robertsonian translocation (rob) results from fusion of 2 acrocentric chromosomes. Carriers are phe-
notypically normal and are often diagnosed because of recurrent miscarriages, infertility, or aneuploid offspring.
Mortality and site-speciﬁc cancer risks in carriers have not been prospectively investigated. We followed 1,987 car-
riers diagnosed in Great Britain for deaths and cancer risk, over an average of 24.1 years. Standardized mortality
and incidence ratios were calculated comparing the number of observed events against population rates. Overall
mortality was higher for carriers diagnosed before age 15 years (standardized mortality ratio (SMR) = 2.00, 95%
conﬁdence interval (CI): 1.09, 3.35), similar for those diagnosed aged 15–44 years (SMR = 1.06, 95% CI:
0.86–1.28), and lower for those diagnosed aged 45–84 years (SMR = 0.81, 95% CI: 0.68, 0.95). Cancer incidence
was higher for non-Hodgkin lymphoma (standardized incidence ratio (SIR) = 1.90, 95% CI: 1.01, 3.24) and child-
hood leukemia (SIR = 14.5, 95% CI: 1.75, 52.2), the latter particularly in rob(15;21) carriers (SIR = 447.8, 95% CI:
11.3, 2,495). Rob(13;14) carriers had a higher breast cancer risk (SIR = 1.58, 95% CI: 1.12, 2.15). Mortality risks
relative to the population in diagnosed carriers depend on age at cytogenetic diagnosis, possibly reﬂecting age-
speciﬁc cytogenetic referral reasons. Carriers might be at greater risk of childhood leukemia and non-Hodgkin lym-
phoma and those diagnosed with rob(13;14) of breast cancer.
chromosome disorders; cohort studies; cytogenetics; epidemiology; genetics; hematological malignancies;
mortality; neoplasms
Abbreviations: ALL, acute lymphoblastic leukemia; CI, conﬁdence interval; iAMP, intrachromosomal ampliﬁcation; rob,
robertsonian translocation; SIR, standardized incidence ratio; SMR, standardizedmortality ratio.
A balanced robertsonian translocation (rob) involves fusion of
2 acrocentric chromosomes (chromosomes 13, 14, 15, 21, 22)
with subsequent loss of the short arms. They have been found to
form predominantly during female meiosis (1, 2). Individuals
are phenotypically normal but are at higher risk of miscarriages,
infertility, and aneuploid offspring because of the production
of unbalanced gametes. Depending on which chromosomes are
involved, carriers are at higher risk of offspring with trisomy 21
(Down syndrome) or trisomy 13 (Patau syndrome) (3, 4).
Balanced robertsonian translocations represent the most com-
mon chromosomal rearrangement in humans. Newborn surveys
have estimated that they occur in 1 in 1,000 individuals (5–8),
with higher estimates (1 in 800) obtained from surveys of chil-
dren referred for neurodevelopmental disease and congenital
abnormalities (9). Translocations are disproportionately common
between chromosomes 13 and 14 (rob(13;14)) and 14 and 21
(rob(14;21)), with other combinations being rare (10, 11). Carriers
of these translocations have 45 chromosomes, but the resulting
loss of the short arms is presumed inconsequential because the
short arms mainly contain repetitive ribosomal DNA (12, 13).
However, mortality and site-speciﬁc cancer incidence have not
been systematically investigated in carriers.
A predisposition to hematological disorders in carriers of
balanced robertsonian translocations has been suggested (14);
evidence for this and for premalignant conditions is, however,
derived from case reports (14–19). Recently, carriers of rob(15;21)
have been estimated to be at much higher risk of a rare form of
acute lymphoblastic leukemia (ALL) with intrachromosomal
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ampliﬁcation (iAMP) of chromosome 21 (20). This was based
on the ﬁnding that constitutional rob(15;21) in iAMP-ALL
patients was more common than might be expected based on
newborn surveys. Risk of leukemia has, however, not been
prospectively investigated in robertsonian translocation carriers
overall or according to subtype.
To assess risks in individuals with balanced robertsonian
translocations, one needs a cohort design in which large num-
bers of carriers are followed over a long period of time for
mortality and cancer risk. We therefore investigated long-term
risk of mortality and cancer in a cohort of persons diagnosed
as carriers at cytogenetic centers in Great Britain.
METHODS
Information on patients diagnosed with balanced robertso-
nian translocations was obtained from all cytogenetic centers in
Great Britain (n = 27), except for one small center. Records
were collected as far back in time as records had been main-
tained at each center (in most centers from the 1960s or 1970s).
The last year that records were abstracted ranged between
1994 and 2006, depending on when data extraction was con-
ducted at the center, mostly in the late 1990s. Prenatal records
were not retrieved.
Patient information was matched to the National Health
Service Central Register (NHSCR) for England andWales and
for Scotland. These registers hold information on deaths, emi-
grations, and other exits from the National Health Service for
everyone who is registered with a general practitioner, and are
effectively population registers of these countries. Individuals
who could be uniquely identiﬁed (“ﬂagged”) on the National
Health Service Central Register formed the cohort and were
followed up for cancer incidence, death, and loss to follow-up
(such as through emigration). The underlying cause of death,
from death certiﬁcates, was coded to the revision of the Inter-
national Statistical Classiﬁcation of Diseases and Related
Health Problems (ICD) in use at the time of death, and was
subsequently bridge-coded to the ninth revision of the classi-
ﬁcation (21) to give the categories shown below in Results.
Patients were excluded if they were known to have been cyto-
genetically examined as a consequence of a cancer diagnosis.
Permission for this study was obtained from appropriate ethics
committees in the United Kingdom and the national personal
information advisory group.
For each cohort member, we calculated person-years at risk
of death according to sex, 5-year age group, calendar year, and
country (England andWales combined vs. Scotland). Follow-up
started at the date of cytogenetic diagnosis and ended onDecem-
ber 31, 2016, or the 85th birthday, date of death, or date of other
loss to follow-up, whichever was earliest. Follow-up was
censored at age 85 years because at older ages the certiﬁed
cause of death is often inaccurate and national rates are not
available for 5-year age group. Expected cause-speciﬁcmortality
in the cohort was calculated by multiplying the sex-, age-,
calendar year-, and country-speciﬁc person-years at risk in the
cohort by the corresponding national mortality rates. Stan-
dardized mortality ratios were derived as the ratio of observed
to expected deaths, and their 95% conﬁdence intervals were
calculated using exact methods (22). We calculated absolute
excess rates by subtracting the expected from the observed
numbers of deaths, dividing by person-years at risk and mul-
tiplying by 100,000. Analyses were performed with STATA,
version 14.2 (StataCorp LLC, College Station, Texas) (23).
All signiﬁcance tests were 2-sided.
Analyses of cancer incidence were conducted similarly,
except that follow-up started on January 1, 1971 (the date from
which national cancer registrations became available), or from
the date of the cytogenetic test, whichever was later, and follow-
up ended on December 31, 2015, the patient’s 85th birthday,
date of death, or date of other loss to follow-up, whichever was
earliest. Standardized incidence ratios were obtained based on
expected numbers from national cancer incidence rates. Analyses
of all malignancies combined included only neoplasms classi-
ﬁed as malignant according to the International Classiﬁcation
of Diseases, Ninth Revision (21), and excluded nonmelanoma
skin cancer because it is underascertained by the cancer regis-
tries (24). Likewise, analyses according to cancer site included
only those coded to malignant, with the exception of central
nervous system tumors, for which nonmalignant tumors were
also included.
Standardized mortality ratios and standardized incidence
ratios were calculated for the entire cohort, according to sex,
most common type of speciﬁc translocations, age at and cal-
endar period of cytogenetic diagnosis, and attained age. In order
to investigate the possibility that mortality or cancer incidence
might have been biased because some subjects were cytoge-
netically tested as a consequence of a prior illness, analyses
were repeated after excluding from follow-up theﬁrst 36months
after cytogenetic diagnosis, because effects of such bias, if pres-
ent, would be expected to “wear off” over time.
RESULTS
We ascertained 2,590 patients with balanced robertsonian
translocations. Among these, insufﬁcient identifying informa-
tion was available for ﬂagging at the National Health Service
Central Register for 574 subjects. A further 12 subjects were
excluded because they could not be followed up and 17 subjects
because they were cytogenetically tested as a consequence of
a diagnosis of cancer. A total of 1,987 subjects were included
in the cohort.
A preponderance of the cohort overall were female (59.4%)
(Table 1). The greatest female excess was among those diag-
nosed aged 15–44 (63.0%), whereas there was no appreciable
female excess among those diagnosed in childhood (50.4%
female) (data not shown). Nearly one-third of carriers (30.8%)
were diagnosed at ages 25–34 years, and the majority of car-
riers (62.4%) were diagnosed during 1990–2006. Robertsonian
translocations most frequently involved chromosomes 13 and 14
(62.8%) or chromosomes 14 and 21 (19.6%), with other com-
binations being much less common.
During mortality follow-up, 257 subjects died, 86 subjects
exited the study when they reached age 85 years, 92 exited
because of emigration or other reasons, and 1,552were followed
until the end of the study. The average follow-up was 24.1 years
per subject (ranging from 0.01 to 55.0 years).
Overall mortality in the cohort relative to the general popu-
lation was nonsigniﬁcantly lower (standardized mortality ratio
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(SMR) = 0.92, 95% conﬁdence interval (CI): 0.81, 1.04), corre-
sponding to 44.5 fewer cases per 100,000 population (Table 2).
Mortality ratios were somewhat lower for males (SMR = 0.87,
95% CI: 0.73, 1.03) than for females (SMR = 0.98, 95% CI:
0.82, 1.17) and lower for subjects diagnosed since 1980 com-
pared with earlier (data not shown). Mortality from congenital
anomalies was signiﬁcantly higher (SMR = 4.72, 95% CI:
1.53, 11.0), with the 5 deaths being from heterogeneous anom-
alies and 4 occurring within 3 years of cytogenetic diagnosis.
Analyses of standardized mortality ratios according to age
at cytogenetic diagnosis showed higher mortality in patients
diagnosed in childhood (for ages 0–14 years, SMR = 2.00,
95% CI: 1.09, 3.35) (Table 3). Cause-speciﬁc mortality was
signiﬁcantly higher for nervous system disease (SMR = 11.9,
95% CI: 3.25, 30.5) and congenital anomalies (SMR = 14.6,
95% CI: 4.74, 34.1). When we repeated the analyses excluding
follow-up <36 months after cytogenetic diagnosis, the stan-
dardized mortality ratios for mortality from all causes (SMR =
0.71, 95% CI: 0.19, 1.83) and from congenital abnormalities or
nervous system disease were no longer signiﬁcantly higher
(data not shown).
Mortality among subjects diagnosed at ages 15–44 years
was similar to that in the general population (SMR = 1.06, 95%
CI: 0.86, 1.28). In those diagnosed at age 45 years or later, mor-
tality was signiﬁcantly lower (SMR = 0.81, 95%CI: 0.68, 0.95)
(Table 3), to a similar extent in men and women (SMR = 0.82
and 0.80, respectively; data not shown). Risk was lower in par-
ticular for circulatory disease (SMR = 0.76, 95% CI: 0.58, 0.99),
including ischemic heart disease (SMR = 0.57, 95% CI: 0.36,
0.85) and cardiac disease (SMR = 0.59, 95% CI: 0.35, 0.94)
(data not shown). Analyses of mortality from cancer showed a
lower risk for colorectal cancer in carriers overall, but no asso-
ciation for other cancer sites (Table 4).
Mortality for the 2 main types of translocations, rob(13;21)
and rob(14;21), separately were not materially different from
the overall results except for higher mortality of diseases of the
nervous system in rob(14;21) carriers (Web Table 1), and all
deaths from myeloma occurred in rob(13;14) carriers (for over-
all follow-up, SMR = 5.02, 95% CI: 1.37, 12.9; and for ≥36
months of follow-up, SMR = 2.44, 95% CI: 0.50, 7.14) (data
not shown).
The analyses of cancer incidence included 1,981 subjects
(Table 4). During follow-up, 202 malignant neoplasms and 4
nonmalignant nervous system tumors occurred. Risk was high-
er for non-Hodgkin lymphoma (standardized incidence ratio
(SIR) = 1.90, 95% CI: 1.01, 3.24). The cases occurred 5–31
years after cytogenetic diagnosis, and the standardized inci-
dence ratio remained signiﬁcant after excluding the ﬁrst 36
months of follow-up. Twelve of the 13 cases involved chro-
mosome 14, including 9 with rob(13;14) (for rob(13;14) car-
riers, SIR = 2.12, 95% CI: 0.97, 4.03) (Web Table 2). Risks
for other types of hematological cancer in the patients overall
were not higher (Table 4).
Risk of breast cancer incidence was not signiﬁcantly higher
overall (SIR = 1.27, 95%CI: 0.94, 1.67) (Table 4) or according
to age at cytogenetic diagnosis (SIR = 0 for ages <15 years,
1.26 for ages 15–44 years, and 1.39 for ages 45–84 years)
(data not shown). Risk was signiﬁcantly higher, however, in rob
(13;14) carriers (SIR = 1.58, 95% CI: 1.12, 2.15), but not
rob(14;21) carriers (SIR = 0.73, 95% CI: 0.27, 1.59) (Web
Table 2). After excluding follow-up in the ﬁrst 36 months
after cytogenetic diagnosis, the standardized incidence ratio
for breast cancer in rob(13;14) carriers remained signiﬁcantly
Table 1. Characteristics of the Cohort of Persons Cytogenetically
DiagnosedWith Balanced Robertsonian Translocations, Great
Britain, 1962–2006
Characteristic No. of Persons % Person-Years
Sex
Male 807 40.6 19,355
Female 1,180 59.4 28,544
Age at diagnosis, years
0–4 240 12.1 6,306
5–14 110 5.5 3,284
15–24 318 16.0 8,489
25–34 612 30.8 15,033
35–44 333 16.8 7,831
45–64 289 14.5 6,038
65–84 85 4.3 918
Year of diagnosis
1962–1969 121 6.1 4,064
1970–1979 181 9.1 6,351
1980–1989 445 22.4 12,315
1990–2006 1,240 62.4 25,169
Year of birth
Before 1950 544 27.4 12,926
1950–1969 935 47.1 23,079
1970–1989 378 19.0 9,302
1990–2005 130 6.5 2,592
Chromosomes involved
13;13 2 0.1 58
13;14 1,248 62.8 29,967
13;15 55 2.8 1,225
13;21 20 1.0 490
13;22 20 1.0 483
14;14 5 0.3 100
14;15 52 2.6 1,129
14;21 390 19.6 9,438
14;22 57 2.9 1,303
15;15 2 0.1 35
15;21 35 1.8 816
15;22 35 1.8 942
21;21 6 0.3 179
21;22 38 1.9 1,101
22;22 10 0.5 277
Othera 12 0.6 356
Total 1,987 100.0 47,899
a Including 7 robertsonian translocations between 2 D-group chro-
mosomes, 4 between a D- and G-group chromosome, and 1 patient
mosaic for 2 different robertsonian translocations.
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higher (data not shown). Risk of colorectal cancer was border-
line signiﬁcantly lower in rob(13;14) carriers (SIR = 0.45,
95% CI: 0.17, 0.99) (Web Table 2).
In analyses of hematological disorders according to attained
age, carriers were at higher risk of leukemia diagnosed in child-
hood (for ages 0–14 years, SIR = 14.5, 95% CI: 1.75, 52.2)
(Table 5). The 2 cases were diagnosed with acute lymphoblastic
leukemia 2 and 10 years after cytogenetic diagnosis, respec-
tively. One patient had a constitutional translocation rob(15;21)
(for leukemia of any type at ages 0–14 years among rob(15;21)
carriers, SIR = 447.8, 95% CI: 11.3, 2,495) and the other rob
(13;14) (among rob(13;14) carriers, SIR = 11.74, 95% CI: 0.30,
65.4) (data not shown). Among the 13 cases with non-Hodgkin
lymphoma, 11 were diagnosed at age 45 years or older (SIR =
1.89, 95% CI: 0.95, 3.38). In analyses according to age at cyto-
genetic diagnosis, standardized incidence ratios were not signiﬁ-
cantly higher for hematological disorders (Web Table 3).
We ascertained reasons for referral for cytogenetic testing
among 250 patients postnatally diagnosed at theWessex Regional
Genetics Laboratory. Among subjects cytogenetically tested
younger than age 20 years, the main reasons were a family
history of robertsonian translocation or other abnormality (48%)
or abnormalities and developmental delay (34%). Among those
diagnosed at ages 20–44 years, the main reasons were offspring
with a robertsonian translocation or Down syndrome (40%),
other family history of such abnormalities (28%), or fertility-
related problems (24%). Subjects diagnosed at older ages were
referred predominantly because theywere parents (62%) or other
relatives (24%) of individuals with cytogenetic abnormalities.
DISCUSSION
Our study is, to our knowledge, the ﬁrst to report on mor-
tality and site-speciﬁc cancer risks in carriers of balanced
robertsonian translocations. It has the strength that it was pro-
spective, based on carriers from a large population over a long
period of follow-up, and that mortality and cancer outcome
data were collected in an unbiased manner and could be com-
pared against population rates. Overall mortality rates were
similar to those expected based on general population rates,
but we observed differences in age-speciﬁc mortality. Cancer
risks overall were also similar, consistent with the only other,
much smaller, cohort study of 730 carriers from Denmark,
which reported only on overall cancer incidence (25). How-
ever, site-speciﬁc analyses in our study showed signiﬁcant,
higher risks of non-Hodgkin lymphoma and childhood leu-
kemia in carriers overall and of breast cancer in rob(13;14)
carriers.
Table 2. Cause-SpeciﬁcMortality Among 1,987 Persons Cytogenetically DiagnosedWith Balanced Robertsonian Translocations, Great Britain,
1962–2006
ICD-9 Code Cause No. of Deaths SMR 95%CI AERa
140–208 All malignant neoplasms 81 0.88 0.70, 1.10 −22.5
240–279 Endocrine, nutritional, metabolic, immunity 3 0.71 0.15, 2.07 −2.6
290–319 Mental disorders 4 0.70 0.19, 1.80 −3.5
320–389 Diseases of the nervous system 12 1.57 0.81, 2.75 9.1
390–459 Diseases of the circulatory system 83 0.86 0.69, 1.07 −28.4
410–414 Ischemic heart disease 42 0.77 0.55, 1.04 −26.4
410 Acutemyocardial infarction 29 0.91 0.61, 1.30 −6.3
420–429 Other heart disease 8 1.01 0.44, 1.99 0.20
430–437 Cerebrovascular disease 20 0.93 0.57, 1.43 −3.2
460–519 Diseases of the respiratory system 30 1.01 0.68, 1.44 0.70
480–486 Pneumonia 11 1.11 0.55, 1.98 2.2
490–494, 496 Chronic lower respiratory disease 10 0.67 0.32, 1.24 −10.2
520–579 Diseases of the digestive system 13 0.90 0.48, 1.53 −3.1
570–572, 573.0, 573.3–573.9 Liver disease 7 1.05 0.42, 2.17 0.71
580–629 Diseases of the genitourinary system 3 0.89 0.18, 2.59 −0.80
710–739 Musculoskeletal system and connective tissue 1 0.63 0.02, 3.48 −1.30
740–759 Congenital anomalies 5 4.72b 1.53, 11.0 8.2
800–999 Accidents and violence 14 0.96 0.52, 1.60 −1.33
001–999 All causesc 257 0.92 0.81, 1.04 −44.5
Abbreviations: AER, absolute excess rate; CI, conﬁdence interval; ICD-9, International Classiﬁcation of Diseases, Ninth Revision; SMR, stan-
dardizedmortality ratio.
a Number of excess deaths per 100,000 population per annum.
b Two-sidedP value based on exact method;P < 0.01.
c Includes 8 deaths from causes not listed individually in the table (4 unknown, 2 senility, 1 infarction of spleen, and 1 myelodysplastic
syndrome).
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The years for which we extracted records varied according
to cytogenetic center depending on the years the center was
operational, availability of historical records, and the calendar
period of extraction. We estimate that we extracted infor-
mation for 55% of all individuals diagnosed in Great Britain
during 1962–2006. This is unlikely to lead to bias, however,
as the availability of records for operational reasons is ex-
pected to be unrelated to later cancer incidence and mortal-
ity. Most carriers are not detected unless they get referred for
cytogenetic testing for experiencing reproductive problems or
abnormalities in offspring. We estimate, for the years we have
the greatest numbers of carriers (1988–1998), that 20% of car-
riers are eventually diagnosed, based on a newborn prevalence
of 1 in 1,000 and the number of births in Great Britain dur-
ing this period. Our study is therefore of patients with robert-
sonian translocations who are diagnosed, but from a clinical
and counselling perspective this is the group of cases of rele-
vance. However, the selective forces that led to diagnosis are
then important in the interpretation of our results. Information
from the Wessex center showed that in subjects diagnosed in
childhood, referral for cytogenetic testing, and hence diagno-
sis of a balanced robertsonian translocation, was often a con-
sequence of existing morbidity. The effect of such referral bias
would be expected to be greatest in the early years after cyto-
genetic diagnosis and diminish with time. The observation that
standardized mortality ratios for patients diagnosed with bal-
anced robertsonian translocation in childhood were not higher
after excluding the ﬁrst 36 months of follow-up suggests that
the higher standardized mortality ratios for these patients were
due to such bias.
The majority of carriers were diagnosed at ages 15–44 years,
with their referral reasons related to infertility or having off-
spring with cytogenetic abnormalities. We observed that mortal-
ity in this groupwas comparable to that of the general population
but that mortality was lower among carriers diagnosed at
ages 45 or older, in particular from circulatory disease. The
age-speciﬁcity of this ﬁnding suggests a role of referral bias
rather than a genetic effect. Data on referral reasons in Wes-
sex suggest that older subjects are usually referred for testing
because of cytogenetic abnormality in their own children or
other relatives. Lower mortality in subjects diagnosed later in
life might therefore be due to a selective referral of subjects who
are physically well enough to have had children of their own and
willing and well enough to be cytogenetically tested (26). Addi-
tionally, although the national health system ofGreat Britain pro-
vides access to cytogenetic testing free of charge to those who
are referred, it is possible that carriers who are diagnosed at later
ages have a higher socioeconomic status, which is associated
with lower overall and cardiovascular mortality, than the general
population (27).
The reason for referral for cytogenetic testing, and hence
degree of referral bias, might also depend on karyotype or sex
(4, 28). We observed a strong preponderance of female car-
riers overall, which was most pronounced at female reproduc-
tive ages, whereas there was no female excess among carriers
diagnosed in childhood. The reason for the disparity in numbers
Table 3. Cause-SpeciﬁcMortality Among 1,987 Persons Cytogenetically DiagnosedWith Balanced Robertsonian Translocations, According to
Age at Cytogenetic Diagnosis, Great Britain, 1962–2006
ICD-9 Code Cause
Age at Cytogenetic Diagnosis, years
0–14 15–44 45–84
No. of
Deaths SMR 95%CI
No. of
Deaths SMR 95%CI
No. of
Deaths SMR 95%CI
140–208 All malignant neoplasms 0 0.00 0.0, 3.08 34 0.96 0.67, 1.34 47 0.85 0.63, 1.13
240–279 Endocrine, nutritional, metabolic,
immunity
0 0.0 0.0, 22.5 1 0.63 0.02, 3.52 2 0.80 0.10, 2.90
290–319 Mental disorders 0 0.0 0.0, 13.5 2 1.06 0.13, 3.82 2 0.57 0.07, 2.05
320–389 Diseases of the nervous system 4 11.9a 3.25, 30.5 4 1.31 0.36, 3.34 4 0.95 0.26, 2.43
390–459 Diseases of the circulatory system 0 0.0 0.0, 5.03 28 1.18 0.78, 1.70 55 0.76b 0.58, 0.99
460–519 Diseases of the respiratory system 1 2.83 0.07, 15.8 9 1.25 0.57, 2.37 20 0.91 0.56, 1.40
520–579 Diseases of the digestive system 1 2.50 0.06, 13.9 6 0.84 0.31, 1.83 6 0.86 0.32, 1.88
580–629 Diseases of the genitourinary
system
0 0.0 0.0, 103.9 1 1.19 0.03, 6.64 2 0.80 0.10, 2.88
710–739 Musculoskeletal system and
connective tissue
0 0.0 0.0, 141.0 1 1.97 0.05, 11.0 0 0.0 0.0, 3.46
740–759 Congenital anomalies 5 14.6a 4.74, 34.1 0 0.0 0.0, 6.93 0 0.0 0.0, 19.9
800–999 Accidents and violence 1 0.48 0.01, 2.65 10 1.11 0.53, 2.05 3 0.84 0.17, 2.47
001–999 All causesc 14 2.00b 1.09, 3.35 99 1.06 0.86, 1.28 144 0.81b 0.68, 0.95
Abbreviations: CI, conﬁdence interval; ICD-9, International Classiﬁcation of Diseases, Ninth Revision; SMR, standardizedmortality ratio.
a Two-sidedP value based on exact method;P < 0.001.
b Two-sidedP value based on exact method;P < 0.05.
c Includes 8 deaths from causes not listed individually in the table (4 unknown, 2 senility, 1 infarction of spleen, and 1 myelodysplastic
syndrome).
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by sex is therefore likely to be connected to reproduction-related
reasons for referral. We found, however, no evidence that mor-
tality rates were different between rob(13;14) and rob(14;21)
carriers or between males and females.
Rob(13;14) and rob(14;21) constituted 82.4% of all trans-
locations in our cohort, in range with previous estimates of
74%–85% (10, 11). The preferential formation of these karyo-
types is thought to be a consequence of recombination between
inverted homologous sequences shared by these chromosomes
(11, 29). Breakpoints in these translocations have been reported
to be very consistent and localized to speciﬁc regions in the
proximal acrocentric short arms, preferentially in satellite III
DNA, resulting in a dicentric chromosome (12, 29). Transloca-
tions involving other combinations of chromosomes are much
less common, in particular between homologous chromo-
somes. For these translocations, breakpoints are variable, and it
is thought that theymight be formed through a different mecha-
nism (2, 11–13).
Table 4. Cancer Incidence andMortality in Persons Cytogenetically DiagnosedWith BalancedRobertsonian
Translocations, Great Britain, 1962–2006
ICD-9 Code Cancer Site
Incidence (n = 1,981) Mortality (n = 1,987)
No. SIR 95%CI No. SMR 95%CI
140–171, 173–208 All malignant neoplasmsa 202 1.05 0.91, 1.20 81 0.88 0.70, 1.10
141–149 Tongue, mouth, pharynx 6 1.41 0.52, 3.07 1 0.68 0.02, 3.79
150 Esophagus 3 0.69 0.14, 2.02 5 1.24 0.40, 2.88
151 Stomach 6 1.21 0.45, 2.62 2 0.55 0.07, 1.99
153, 154 Colon and rectum 14 0.65 0.35, 1.09 3 0.33b 0.07, 0.97
155 Liver 1 0.52 0.01, 2.91 1 0.55 0.01, 3.09
157 Pancreas 4 0.92 0.25, 2.35 5 1.18 0.38, 2.75
162 Lung 23 0.88 0.56, 1.32 18 0.79 0.47, 1.26
163 Pleura 2 1.93 0.23, 6.97 0 0.0 0.0, 10.3
170 Bone 1 2.76 0.07, 15.4 0 0.0 0.0, 18.5
172 Cutaneousmelanoma 8 1.08 0.47, 2.14 1 0.82 0.02, 4.57
174, 175 Breast 50 1.27 0.94, 1.67 13 1.42 0.76, 2.44
179,182 Corpus uteri 5 0.95 0.31, 2.21 0 0.0 0.0, 3.51
180 Cervix 2 0.55 0.07, 2.00 0 0.0 0.0, 3.18
183 Ovary 6 1.09 0.40, 2.36 1 0.32 0.01, 1.81
184.0–184.4 Vagina and vulva 2 2.20 0.27, 7.95 1 4.12 0.10, 22.9
185 Prostate 23 1.42 0.91, 2.14 6 1.53 0.56, 3.34
186 Testis 1 0.67 0.02, 3.72 0 0.0 0.0, 44.0
187.1–187.4 Penis 2 7.01 0.85, 25.3 0 0.0 0.0, 56.7
188 Bladder and urethra 5 0.85 0.28, 1.98 4 1.66 0.45, 4.26
189 Kidney and ureter 1 0.20 0.01, 1.13 1 0.49 0.01, 2.71
190 Eye 1 2.46 0.06, 13.7 0 0.0 0.0, 50.0
191, 192, 225, 237.5, 237.6,
237.9, 239.6
Nervous system tumors,
including benign tumorsc
8 1.47 0.64, 2.90 3 0.95 0.20, 2.78
193 Thyroid 2 1.13 0.14, 4.06 0 0.0 0.0, 18.8
196.0–199.1 Unknown primary site 5 0.81 0.26, 1.88 6 0.88 0.32, 1.91
200, 202 Non-Hodgkin lymphoma 13 1.90b 1.01, 3.24 4 1.57 0.43, 3.24
201 Hodgkin disease 1 0.79 0.02, 4.39 1 3.68 0.09, 20.5
203 Myeloma 4 1.76 0.48, 4.48 4 3.06 0.83, 7.81
204–208 Leukemia 6 1.39 0.51, 3.02 0 0.0 0.0, 1.61
Abbreviations: CI, conﬁdence interval; ICD-9, International Classiﬁcation of Diseases, Ninth Revision; SIR, stan-
dardized incidence ratio; SMR, standardizedmortality ratio.
a All malignant neoplasms except nonmelanoma skin cancer; 1 death (from malignancy of “other” part of digestive
system) and 1 incident cancer (maxillary sinus) were not listed individually.
b Two-sidedP value based on exact method;P < 0.01.
c The 8 observed incident tumors included comprise 4 malignant cancers of the brain and 4 benign neoplasms of
the meninges. For England and Wales, benign nervous system neoplasms were included from the year 1971 and for
Scotland from the year 2000. The tumors of the 3 persons who died with nervous system tumors were all malignant.
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The risk of non-Hodgkin lymphoma in balanced robertso-
nian translocation carriers does not appear to have been inves-
tigated before, and while acquired reciprocal translocations
are common in lymphoma and leukemia (30), the mechanism
by which carriers might be predisposed is not clear. Pathak
(14) proposed in 1986 that constitutional translocations, specif-
ically t(13;14), might predispose to T- or B-cell malignancies,
depending on the breakpoint in chromosome 14. Pathak postu-
lated that predisposition to T-cell malignancy might result due
to a break in 14q11 (T-cell alpha-receptor locus), whereas pre-
disposition to a B-cell malignancy, which includes most
non-Hodgkin lymphomas, could be due to a tandem t(13;14)
translocation with a breakpoint at 14q32. It is not clear, how-
ever, how the breakpoints involved in balanced robertsonian
translocations could affect predisposition tomalignancy.Welborn
(31) reported that acquired robertsonian translocations occur
in hematological malignancies in 1 in 300–400 patients and that
60% of these translocations are isochromosomes 13, 14, or 21.
Li et al. (20) recently estimated that constitutional rob(15;21)
carriers are at >2,700-fold increased risk of iAMP21-ALL, a
rare form of ALL involving ampliﬁcation of chromosome 21,
and proposed a novel mechanism for cancer predisposition.
However, their risk estimate was based on the number of con-
stitutional rob(15;21) carriers in a series of iAMP-ALL cases
and the estimated frequency of rob(15;21) from newborn sur-
veys. Our study is the ﬁrst prospective investigation of this
hypothesis. Rob(15;21) is very rare, with our cohort including
only 35 carriers, including 5 karyotyped when aged <15 years.
One carrier developed ALL when aged <15 years, correspond-
ing to a signiﬁcant ~450-fold increased risk, albeit with a wide
conﬁdence interval. We estimate that, if this association were
causal, the cumulative risk of leukemia (of all subtypes) to the
age of 15 years in t(15;21) carriers is 28% (between 0.8%
and 83% based on the conﬁdence interval of the SIR). Among
the 500–600 new childhood cases of leukemia in Great Britain
annually, about 4 might be t(15;21) carriers, but our estimates
are uncertain because they are based on 1 case only. We have
no information on tumor proﬁle and therefore do not know
whether our case had iAMP-ALL, given that IAMP consti-
tutes only 2.1% of all ALL cases (32), but iAMP-ALL patients
have been reported to be somewhat older than ALL patients
overall (20), consistent with our patient. Our study therefore
supports the hypothesis of increased susceptibility of rob(15;21)
carriers to acute lymphoblastic leukemia.
There are no previous data on breast cancer risk in bal-
anced robertsonian translocation carriers. The observed sig-
niﬁcantly higher risk in rob(13;14) carriers could be a result
of chance or because nulliparity and delayed child birth are
risk factors for breast cancer. However, given the age-speciﬁc
differences in referral reasons, the similar standardized incidence
ratios for women cytogenetically diagnosed at ages 15–44 and
45–84 years argues somewhat against the latter. Higher breast
cancer rates could also arise if our cohort is of higher socioeco-
nomic proﬁle than the general population overall, breast cancer
rates being higher in higher socioeconomic strata (33). How-
ever, alternatively, it might be that the ﬁnding reﬂects a previ-
ously undiscovered genetic cause.
We also observed lower mortality from colorectal cancer in
carriers overall and lower incidence of this cancer in rob(13;14)
carriers but not in carriers overall. Mortality, but not incidence,
of myeloma in rob(13;14) carriers was higher. Given that the
relative risks were not consistent between analyses, we regard
these results as inconclusive, and the ﬁndings would need reex-
amination in other studies.
In conclusion, our study suggests that subjects diagnosed
with balanced robertsonian translocations might be at increased
risk of childhood leukemia and non-Hodgkin lymphoma, and
those diagnosed with rob(13;14) might have a higher breast
cancer risk, but that their mortality is not higher compared with
that in the general population. These ﬁndings might be related
to genetic factors as well as to factors associated with reasons
for referral for cytogenetic testing.
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